Fouremm,

Your Estimated Enterprise value guess of $8 to $12 USD ($2.5 Billion USD ) with an FDA BTD is probably pretty close to the Deloitte report.   My issue with RVX management is that they seen to be caught between rock and hardplace  for future finances with the major insider investors, Hepalink, EAstern, NTN Biotech, Oristar etc. Those insiders want to accumulate as many shares as possible  on the cheap and may have probably  warned RVX not to promote and excite the market so they continue to add shares IMO , They know the end game is worth $2.5 to $5 Billion in a buyout after Betonmace2  , The chances of success are much higher with the primary endpoints now. But at the same time any ongoing  BP discussion for a CVR or partnership deal makes it hard to value RVX now when it trading at micro cap value of around $200 Million .  BP has a BOD and to give 20 times market in an eventual is laughable to a large BP board IMO . The multiples to a buyout are too high   Thus the disconnect of RVX trying to get the right price they feel the science is worth.   You would think that if Deloitte valuation of  RVX in your range of $2,5 Billion that BP would have that same value determined based on the potential of the BTD.  I wondering if a  BP deal is still in the works or going it alone only helps our insiders get more chares on the cheap to finish off the trial but all along being at the mercy of always need money with the insider finances. We NEED a BP partnership DEAL only IMO.